In order to inform and protect consumers from the risks of sunlamp products such as tanning beds, the FDA is changing the classification and requiring a black box warning to be clearly visible on each indoor tanning device. The warning will emphasize the heighten risk for those younger than 18 or for people with a family history of skin cancer, and include language advising regular skin cancer evaluations for persons repeatedly exposed to UV radiation.
In a statement released on March 21, 2014, the U.S Food and Drug Administration announced that the FDA approved a new drug to treat adults with active psoriatic arthritis (PsA). The new drug is “Otezla”, and Bill Berkot, in “Update 2- U.S.
The FDA recently approved a new drug application to treat tinea corporis, tinea cruris, and tinea pedis. The drug is luliconazole, a topical azole antifungal cream.
Luliconazole is approved for a 1-week, once-daily treatment regimen treatment course in adults over 18 years old with tinea corporis or tinea cruris. Treatment for interdigital tinea pedis is once daily for 2 weeks.